We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Insomnia and Osteoarthritis Study

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 11, 2006
Last Update Posted: March 11, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Michael T. Smith, Ph.D, Johns Hopkins University
September 8, 2006
September 11, 2006
March 11, 2014
January 2006
December 2013   (Final data collection date for primary outcome measure)
  • Two-week average sleep diary and actigraphy measures of Wake After Sleep Onset Time; measured at six weeks.
  • Laboratory Pain Sensitivity Measures; levels at six weeks.
  • Two-week average diary ratings of pain severity; score at six weeks.
Same as current
Complete list of historical versions of study NCT00374556 on ClinicalTrials.gov Archive Site
  • WOMAC Disability & Joint Stiffness Indices; measured at 12 weeks.
  • Quality of Life (SF-36); measured at 12 weeks.
  • Insomnia Severity Index; measured at 12 weeks.
Same as current
Not Provided
Not Provided
Insomnia and Osteoarthritis Study
The Efficacy of Eszopiclone (Lunesta) for Chronic Insomnia Associated With Osteoarthritis.
This research is being done to evaluate the effects of a sleeping pill (eszopiclone, Lunesta)in patients with arthritis of the knee who also suffer from chronic insomnia. This study will test whether Lunesta improves sleep, pain sensitivity, and daytime symptoms in patients with knee pain.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
  • Osteoarthritis
  • Insomnia
Drug: eszopiclone, 2 mg, qhs
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-64
  • Diagnosed with and under physicians care for osteoarthritis of the knee according to American College of Rheumatology Criteria with radiographic evidence demonstrating at least grade 1 OA
  • Report at least typical arthritic pain>4 out of 10 (0=no pain, 10=the most extreme pain imaginable)
  • Meet DSM-IV and ICSD-R criteria for either primary (psychophysiologic) insomnia or insomnia secondary to osteoarthritis
  • Insomnia symptoms must include problems with middle of the night awakenings
  • Insomnia symptom duration > 6 months
  • Baseline, 2-week, sleep diary average wake after sleep onset time >30 minutes
  • Baseline self-reported total sleep time < 6.5 hours per night
  • Patients taking NSAID therapy for pain must be on a stable dose for a period of at least one month prior to initiating the study

Exclusion Criteria:

  • Intrinsic sleep disorders other than insomnia (sleep apnea, periodic limb movement disorder, etc)
  • Significant rheumatologic or chronic pain disorders other than osteoarthritis of the knee, including fibromyalgia or the complaint of widespread pain impacting 4 quadrants, complex regional pain syndrome, post herpetic neuralgia, etc)
  • Major medical disease (including, hepatic impairment, chronic obstructive pulmonary disease/compromised respiratory function, cancer, dementia, diabetes, congestive heart failure, cerebrovascular disease, raynaud's syndrome)
  • Active major psychiatric disorders (including dementia or cognitive impairment) and history of schizophrenia or bipolar I disorder
  • History of serious suicide attempt; 6) history of alcohol or substance (including prescription medications) abuse
  • Pregnancy or plans to become pregnant within 6 months
  • Intraarticular steroid injection within the past month
  • Regular (>3 days/week) use of antidepressants, antipsychotics, and mood stabilizers, within the past two months
  • Regular (> 3/week) use of myorelaxants, narcotics, sedative hypnotics, and anticonvulsants within the past one month
  • Unwilling or unable to discontinue all use of the medications listed in #10 for two weeks prior to starting the study
  • Unwilling or unable to discontinue all centrally acting agents and all analgesic usage within 24 hours of pain testing sessions
  • Refusal to provide consent to contact patient's physician to establish diagnosis and obtain medical record information
  • Regular tobacco or nicotine use
  • Heavy caffeine use [(>2 cups of coffee/day (equivalent)
  • History of previous allergic reaction or severe side effects to sedative hypnotics
  • Use of potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, troleandomycin, ritonavir, nelfinavir)
  • In addition, subjects will undergo in-laboratory blood tests prior to receiving drug and will be excluded from further participation if they exhibit: a) positive pregnancy test, b) positive toxicology (benzodiazepine, opioids, THC, alcohol, and stimulants), c) abnormal liver enzyme panel
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Michael T. Smith, Ph.D, Johns Hopkins University
Johns Hopkins University
Not Provided
Principal Investigator: Michael T. Smith, Ph.D. Johns Hopkins University
Johns Hopkins University
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top